Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tissue Plasminogen Activator | 18 | 2022 | 296 | 7.270 |
Why?
|
| Thrombolytic Therapy | 17 | 2022 | 233 | 7.260 |
Why?
|
| Brain Ischemia | 18 | 2022 | 665 | 7.230 |
Why?
|
| Stroke | 26 | 2022 | 2163 | 7.050 |
Why?
|
| Fibrinolytic Agents | 13 | 2022 | 377 | 5.050 |
Why?
|
| Astacoidea | 11 | 2019 | 12 | 3.680 |
Why?
|
| Risk Factors | 24 | 2022 | 5731 | 2.050 |
Why?
|
| Morphine | 5 | 2017 | 76 | 2.030 |
Why?
|
| Ischemic Attack, Transient | 3 | 2021 | 167 | 1.990 |
Why?
|
| Hypertension | 6 | 2022 | 1535 | 1.940 |
Why?
|
| Telemedicine | 5 | 2022 | 700 | 1.920 |
Why?
|
| Dyslipidemias | 3 | 2021 | 98 | 1.910 |
Why?
|
| Aged, 80 and over | 19 | 2021 | 4848 | 1.610 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2022 | 50 | 1.480 |
Why?
|
| Retrospective Studies | 20 | 2022 | 7277 | 1.470 |
Why?
|
| Coronary Artery Disease | 3 | 2022 | 696 | 1.470 |
Why?
|
| Registries | 8 | 2021 | 733 | 1.420 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2022 | 142 | 1.370 |
Why?
|
| Reward | 8 | 2019 | 201 | 1.340 |
Why?
|
| Neuroanatomy | 2 | 2019 | 14 | 1.300 |
Why?
|
| Academic Performance | 2 | 2019 | 11 | 1.290 |
Why?
|
| Walking | 3 | 2021 | 241 | 1.190 |
Why?
|
| Students, Medical | 2 | 2021 | 210 | 1.170 |
Why?
|
| Proto-Oncogene Proteins c-fos | 3 | 2012 | 114 | 1.150 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2019 | 148 | 1.140 |
Why?
|
| Locomotion | 3 | 2014 | 135 | 1.100 |
Why?
|
| Aged | 20 | 2021 | 14862 | 1.090 |
Why?
|
| Male | 33 | 2022 | 37321 | 1.060 |
Why?
|
| Brain | 7 | 2019 | 2176 | 1.060 |
Why?
|
| Substance-Related Disorders | 4 | 2020 | 1242 | 1.050 |
Why?
|
| Hippocampus | 3 | 2017 | 471 | 1.040 |
Why?
|
| Quinine | 2 | 2016 | 8 | 1.040 |
Why?
|
| Sex Characteristics | 2 | 2018 | 295 | 1.030 |
Why?
|
| Hibernation | 3 | 2017 | 8 | 0.990 |
Why?
|
| Methamphetamine | 2 | 2017 | 132 | 0.970 |
Why?
|
| Narcotics | 4 | 2014 | 65 | 0.960 |
Why?
|
| Cocaine | 3 | 2017 | 555 | 0.960 |
Why?
|
| Female | 28 | 2022 | 38074 | 0.940 |
Why?
|
| Middle Aged | 20 | 2021 | 21147 | 0.940 |
Why?
|
| Humans | 37 | 2022 | 68618 | 0.920 |
Why?
|
| Motor Activity | 5 | 2017 | 621 | 0.920 |
Why?
|
| Atrial Fibrillation | 3 | 2021 | 249 | 0.910 |
Why?
|
| Mole Rats | 4 | 2013 | 8 | 0.870 |
Why?
|
| Hypoxia | 2 | 2015 | 169 | 0.840 |
Why?
|
| Heart Failure | 2 | 2022 | 1180 | 0.840 |
Why?
|
| Risk Assessment | 4 | 2020 | 2007 | 0.780 |
Why?
|
| Sex Factors | 6 | 2021 | 1266 | 0.780 |
Why?
|
| Logistic Models | 6 | 2021 | 1420 | 0.770 |
Why?
|
| Behavior, Animal | 6 | 2019 | 470 | 0.770 |
Why?
|
| Antihypertensive Agents | 3 | 2021 | 498 | 0.760 |
Why?
|
| Treatment Outcome | 10 | 2022 | 7029 | 0.750 |
Why?
|
| Anatomy | 1 | 2021 | 36 | 0.750 |
Why?
|
| Disease Models, Animal | 5 | 2015 | 2550 | 0.720 |
Why?
|
| Carotid Stenosis | 1 | 2021 | 163 | 0.700 |
Why?
|
| Models, Animal | 2 | 2019 | 252 | 0.700 |
Why?
|
| Anticholesteremic Agents | 1 | 2020 | 49 | 0.700 |
Why?
|
| Dissection | 1 | 2019 | 29 | 0.680 |
Why?
|
| Cholesterol | 1 | 2020 | 331 | 0.670 |
Why?
|
| Smokers | 1 | 2021 | 200 | 0.660 |
Why?
|
| Incidence | 5 | 2021 | 1603 | 0.630 |
Why?
|
| Hypoxia-Ischemia, Brain | 2 | 2009 | 56 | 0.620 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 212 | 0.620 |
Why?
|
| Motivation | 2 | 2019 | 561 | 0.610 |
Why?
|
| Time Factors | 9 | 2021 | 4655 | 0.600 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 163 | 0.600 |
Why?
|
| Medicine in the Arts | 1 | 2017 | 7 | 0.600 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 951 | 0.600 |
Why?
|
| Sciuridae | 1 | 2017 | 2 | 0.590 |
Why?
|
| Stereotyped Behavior | 1 | 2017 | 42 | 0.590 |
Why?
|
| Hypoxia, Brain | 1 | 2017 | 16 | 0.590 |
Why?
|
| Glucose | 2 | 2017 | 307 | 0.580 |
Why?
|
| Psychotropic Drugs | 1 | 2017 | 83 | 0.560 |
Why?
|
| Depression | 2 | 2021 | 943 | 0.560 |
Why?
|
| Critical Care | 1 | 2019 | 263 | 0.540 |
Why?
|
| Ciprofloxacin | 1 | 2016 | 30 | 0.540 |
Why?
|
| Schools | 1 | 2017 | 156 | 0.540 |
Why?
|
| Teaching | 1 | 2017 | 169 | 0.530 |
Why?
|
| Comorbidity | 4 | 2021 | 1426 | 0.530 |
Why?
|
| Animals | 17 | 2019 | 20881 | 0.510 |
Why?
|
| Garcinia kola | 1 | 2014 | 1 | 0.500 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2018 | 152 | 0.490 |
Why?
|
| Health Education | 1 | 2017 | 279 | 0.490 |
Why?
|
| Seeds | 1 | 2014 | 23 | 0.490 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2017 | 1745 | 0.490 |
Why?
|
| Oxygen Consumption | 2 | 2012 | 258 | 0.460 |
Why?
|
| Exploratory Behavior | 1 | 2014 | 79 | 0.440 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2014 | 435 | 0.440 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 378 | 0.420 |
Why?
|
| Recombinant Proteins | 3 | 2020 | 742 | 0.410 |
Why?
|
| Multivariate Analysis | 3 | 2020 | 1046 | 0.410 |
Why?
|
| Dietary Supplements | 1 | 2014 | 332 | 0.400 |
Why?
|
| Body Temperature | 1 | 2012 | 116 | 0.400 |
Why?
|
| Obesity | 1 | 2019 | 1076 | 0.400 |
Why?
|
| Smoking | 1 | 2020 | 1452 | 0.390 |
Why?
|
| Curriculum | 3 | 2021 | 575 | 0.370 |
Why?
|
| Cues | 2 | 2011 | 654 | 0.340 |
Why?
|
| Adult | 8 | 2021 | 21403 | 0.340 |
Why?
|
| Conditioning, Classical | 1 | 2009 | 57 | 0.340 |
Why?
|
| Cytoprotection | 1 | 2009 | 39 | 0.330 |
Why?
|
| Demography | 2 | 2020 | 279 | 0.310 |
Why?
|
| South Carolina | 3 | 2020 | 2752 | 0.310 |
Why?
|
| Receptor, Muscarinic M1 | 1 | 2008 | 17 | 0.300 |
Why?
|
| Conditioning, Operant | 2 | 2010 | 241 | 0.300 |
Why?
|
| Hypothermia, Induced | 1 | 2008 | 93 | 0.290 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2008 | 91 | 0.290 |
Why?
|
| Educational Measurement | 2 | 2019 | 254 | 0.280 |
Why?
|
| Extinction, Psychological | 1 | 2008 | 240 | 0.280 |
Why?
|
| Odds Ratio | 2 | 2019 | 880 | 0.270 |
Why?
|
| Age Distribution | 2 | 2018 | 320 | 0.270 |
Why?
|
| Body Mass Index | 2 | 2020 | 867 | 0.270 |
Why?
|
| Quinidine | 2 | 2016 | 15 | 0.260 |
Why?
|
| Area Under Curve | 2 | 2016 | 238 | 0.250 |
Why?
|
| Cross-Over Studies | 2 | 2016 | 260 | 0.240 |
Why?
|
| Drug Interactions | 2 | 2016 | 289 | 0.240 |
Why?
|
| Patient Selection | 2 | 2020 | 592 | 0.240 |
Why?
|
| Age Factors | 2 | 2020 | 1864 | 0.240 |
Why?
|
| Polysomnography | 1 | 2021 | 92 | 0.190 |
Why?
|
| Contraindications, Procedure | 1 | 2020 | 1 | 0.180 |
Why?
|
| Minority Groups | 1 | 2022 | 197 | 0.180 |
Why?
|
| Cholesterol, LDL | 1 | 2021 | 161 | 0.180 |
Why?
|
| Students | 1 | 2022 | 233 | 0.180 |
Why?
|
| Metamorphosis, Biological | 1 | 2019 | 4 | 0.170 |
Why?
|
| Acute Disease | 1 | 2021 | 658 | 0.170 |
Why?
|
| Patient Admission | 1 | 2020 | 99 | 0.170 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2019 | 23 | 0.170 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 109 | 0.170 |
Why?
|
| Cadaver | 1 | 2019 | 136 | 0.170 |
Why?
|
| Random Allocation | 2 | 2011 | 442 | 0.170 |
Why?
|
| ROC Curve | 1 | 2020 | 392 | 0.160 |
Why?
|
| Affect | 1 | 2020 | 218 | 0.160 |
Why?
|
| Histones | 1 | 2019 | 111 | 0.160 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 239 | 0.150 |
Why?
|
| Pandemics | 1 | 2021 | 352 | 0.150 |
Why?
|
| Self Administration | 1 | 2019 | 419 | 0.150 |
Why?
|
| Analysis of Variance | 2 | 2011 | 1040 | 0.150 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 306 | 0.140 |
Why?
|
| Acidosis | 1 | 2017 | 31 | 0.140 |
Why?
|
| Catheters, Indwelling | 1 | 2017 | 72 | 0.140 |
Why?
|
| Awareness | 1 | 2017 | 81 | 0.140 |
Why?
|
| Environmental Exposure | 1 | 2019 | 269 | 0.140 |
Why?
|
| Seasons | 1 | 2017 | 129 | 0.140 |
Why?
|
| Perfusion Imaging | 1 | 2016 | 27 | 0.140 |
Why?
|
| Gene Expression | 1 | 2019 | 770 | 0.140 |
Why?
|
| Schools, Medical | 1 | 2017 | 157 | 0.140 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2016 | 2 | 0.140 |
Why?
|
| Video Recording | 1 | 2017 | 145 | 0.140 |
Why?
|
| Learning | 1 | 2018 | 186 | 0.130 |
Why?
|
| Adenosine Triphosphate | 1 | 2017 | 314 | 0.130 |
Why?
|
| Spatial Behavior | 1 | 2015 | 18 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2017 | 502 | 0.130 |
Why?
|
| Microdialysis | 1 | 2015 | 147 | 0.130 |
Why?
|
| Recovery of Function | 1 | 2019 | 506 | 0.130 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 1851 | 0.130 |
Why?
|
| Young Adult | 2 | 2017 | 5717 | 0.120 |
Why?
|
| Therapeutic Equivalency | 1 | 2014 | 21 | 0.120 |
Why?
|
| Nigeria | 1 | 2014 | 35 | 0.120 |
Why?
|
| Metabolic Clearance Rate | 1 | 2014 | 48 | 0.120 |
Why?
|
| Half-Life | 1 | 2014 | 96 | 0.120 |
Why?
|
| Biotransformation | 1 | 2014 | 69 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 2279 | 0.120 |
Why?
|
| Healthy Volunteers | 1 | 2014 | 78 | 0.120 |
Why?
|
| Disability Evaluation | 1 | 2016 | 298 | 0.120 |
Why?
|
| Behavior, Addictive | 1 | 2018 | 317 | 0.120 |
Why?
|
| Parents | 1 | 2017 | 312 | 0.120 |
Why?
|
| Glutamic Acid | 1 | 2017 | 332 | 0.120 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2014 | 381 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2014 | 411 | 0.110 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 567 | 0.110 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 1465 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2018 | 2358 | 0.100 |
Why?
|
| Videotape Recording | 1 | 2011 | 43 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2800 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2012 | 682 | 0.090 |
Why?
|
| Space Perception | 1 | 2009 | 44 | 0.090 |
Why?
|
| Organ Culture Techniques | 1 | 2009 | 122 | 0.080 |
Why?
|
| Invertebrates | 1 | 2008 | 8 | 0.080 |
Why?
|
| Species Specificity | 1 | 2009 | 303 | 0.080 |
Why?
|
| Nerve Degeneration | 1 | 2009 | 134 | 0.080 |
Why?
|
| Reinforcement Schedule | 1 | 2008 | 59 | 0.080 |
Why?
|
| Microinjections | 1 | 2008 | 130 | 0.080 |
Why?
|
| Thiadiazoles | 1 | 2008 | 7 | 0.080 |
Why?
|
| Muscarinic Agonists | 1 | 2008 | 17 | 0.080 |
Why?
|
| Perinatal Care | 1 | 2008 | 17 | 0.080 |
Why?
|
| Adaptation, Physiological | 1 | 2009 | 189 | 0.080 |
Why?
|
| RNA, Messenger | 1 | 2012 | 1664 | 0.080 |
Why?
|
| Drug-Seeking Behavior | 1 | 2010 | 213 | 0.080 |
Why?
|
| Fetal Diseases | 1 | 2008 | 64 | 0.080 |
Why?
|
| Stress, Physiological | 1 | 2009 | 215 | 0.070 |
Why?
|
| Muscarinic Antagonists | 1 | 2008 | 54 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 2223 | 0.070 |
Why?
|
| Neuropsychological Tests | 1 | 2009 | 517 | 0.070 |
Why?
|
| Oxygen | 1 | 2009 | 386 | 0.070 |
Why?
|
| Cerebral Hemorrhage | 1 | 2008 | 198 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2324 | 0.070 |
Why?
|
| Cell Survival | 1 | 2009 | 901 | 0.070 |
Why?
|
| Child | 1 | 2017 | 6405 | 0.070 |
Why?
|
| Pyridines | 1 | 2008 | 261 | 0.070 |
Why?
|
| United States | 1 | 2018 | 7367 | 0.060 |
Why?
|
| Pregnancy | 1 | 2008 | 2334 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2008 | 2455 | 0.050 |
Why?
|
| Career Choice | 1 | 2022 | 98 | 0.050 |
Why?
|
| Perception | 1 | 2022 | 189 | 0.050 |
Why?
|
| Rats | 1 | 2009 | 5300 | 0.050 |
Why?
|
| Research | 1 | 2022 | 214 | 0.050 |
Why?
|
| Morphine Dependence | 1 | 2010 | 4 | 0.020 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2010 | 92 | 0.020 |
Why?
|